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Background: Potential late effects of treatment for childhood cancer include adiposity, insulin resistance, dyslipidemia, and
hypertension. These risk factors cluster together as metabolic syndrome and increase the risk for development of diabetes mellitus
and cardio- and cerebrovascular disease. Knowledge on risk factors, timely diagnosis, and preventive strategies is of importance
to prevent cardio- and cerebrovascular complications and improve quality of life. Currently, no national cohort studies on the
prevalence and determinants of metabolic syndrome in childhood cancer survivors, including biomarkers and genetic predisposition,
are available.
Objective: The objectives of the Dutch LATER METS study are to assess 1) the prevalence and risk factors of metabolic
syndrome and its separate components, and 2) the potential diagnostic and predictive value of additional biomarkers for surveillance
of metabolic syndrome in the national cohort of adult long-term survivors of childhood cancer.
Methods: This is a cross-sectional study based on recruitment of all survivors treated in the Netherlands between 1963 and
2002. Metabolic syndrome will be classified according to the definitions of the third Adult Treatment Panel Report of the National
Cholesterol Education Program as well as the Joint Interim Statement and compared to reference data. Dual-energy x-ray
absorptiometry scans were performed to assess body composition in more detail. The effect of patient characteristics, previous
treatment, and genetic variation on the risk of metabolic syndrome will be assessed. The diagnostic and predictive value of novel
biomarkers will be tested.
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Results: Patient accrual started in 2016 and lasted until April 2020. A total of 2380 survivors from 7 pediatric oncology hospitals
have participated. From July 2020, biomarker testing, single nucleotide polymorphism analysis, and data analysis will be performed.
Conclusions: The Dutch LATER METS study will provide knowledge on clinical and genetic determinants of metabolic
syndrome and the diagnostic value of biomarkers in childhood cancer survivors. The results of this study will be used to optimize
surveillance guidelines for metabolic syndrome in survivors based on enhanced risk stratification and screening strategies. This
will improve diagnosis of metabolic syndrome and prevent complications.
International Registered Report Identifier (IRRID): DERR1-10.2196/21256
(JMIR Res Protoc 2021;10(1):e21256) doi: 10.2196/21256
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Introduction
Due to increasing survival of patients with childhood cancer,
late side effects have become more prominent. Potential late
effects include adiposity, insulin resistance, dyslipidemia, and
hypertension, which cluster together as metabolic syndrome.
Metabolic syndrome is associated with a higher risk of diabetes
mellitus, as well as cardio- and cerebrovascular morbidity and
mortality later in life [1-3]. The separate components are in
themselves risk factors for diabetes and cardiovascular disease
but, when coexisting, the components can aggravate each other,
leading to an even higher risk of diabetes and cardiovascular
disease [4,5].
Studies in childhood cancer survivors have reported a prevalence
of metabolic syndrome of over 30% after 25 years follow-up,
substantially higher compared to age- and sex-matched controls
(odds ratio 1.76) [6,7]. This apparent risk difference for
metabolic syndrome further increases the elevated risks for
cardiovascular outcomes and endothelial damage from
anthracyclines, alkylating agents, and irradiation [8,9].
Consequently, the mortality due to coronary and cerebrovascular
disease in long-term survivors is up to 12.7 times higher than
in the general population [10-13]. The fact that metabolic
syndrome can be subclinical for many years emphasizes the
need for timely identification of metabolic syndrome in
survivors and early intervention strategies. Lifestyle and diet
advice, exercise, and medication may prevent the development
of diabetes and cardio- and cerebrovascular disease, improving
survival rates and quality of life.
Several underlying conditions have been reported to increase
the risk for (components of) metabolic syndrome in survivors:
growth hormone deficiency, pancreatic beta cell dysfunction,
hypogonadism, hypothyroidism, and altered body composition
with increased intra-abdominal fat [14-19]. Hence, an increased
risk of metabolic syndrome might be associated with treatment
for a brain tumor, treatment with radiotherapy, intensive
chemotherapy, nephrectomy, adrenalectomy, or stem cell
transplantation [7,16,20-32]. The effects of other potentially
harmful treatments, for example corticosteroids, and
patient-related factors such as sex, age, body mass index at
diagnosis, and lifestyle, are still not clear [3]. Also, heterogeneity
in incidence of metabolic syndrome among homogeneously
treated survivors suggests a role of genetic susceptibility [33,34].
A few studies using candidate gene approaches [24,35] as well
as one genome-wide association study [36] have identified
genetic variants that might be associated with development of
metabolic syndrome and its components in survivors. Results
based on these studies have not yet been replicated or
functionally validated.
Multiple definitions of metabolic syndrome have been developed
over the past years. The two most commonly used are those of
the third Adult Treatment Panel Report of the National
Cholesterol Education Program [37] and the Joint Interim
Statement of the International Diabetes Federation; National
Heart, Lung, and Blood Institute; and the American Heart
Association [38]. Both definitions overlap largely but they differ
in waist circumference cut-off point (Table 1). Apart from the
4 components, pro-inflammatory and prothrombotic markers
have been reported to be relevant biomarkers of metabolic
syndrome, as has hyperuricemia [39,40].
Adequate assessment of metabolic syndrome in survivors using
the National Cholesterol Education Program and Joint Interim
Statement definitions has specific challenges, particularly after
abdominal radiotherapy. It has been shown that body mass index
and waist circumference underestimate adiposity due to
deformation of spine, muscles, and fat, particularly in past
treatment eras when higher radiotherapy doses and larger fields
were used [21,41,42]. Similarly, adiposity can be disguised due
to sarcopenic obesity after stem cell transplantation [43,44].
Body composition can be more reliably measured by
dual-energy x-ray absorptiometry, but this is time consuming
and expensive to be implemented for standard follow-up of all
survivors. Serum biomarkers may be more cost-effective
surrogate markers for metabolic syndrome. In smaller survivor
cohorts and in the general population, biomarkers other than
triglycerides and high-density lipoprotein cholesterol that have
been proposed as predictors of metabolic syndrome include
low-density lipoprotein, apolipoprotein-B, leptin, adiponectin,
uric acid, and C-reactive protein [39,45-50].
So far, large studies on clinically diagnosed metabolic syndrome
in survivors are scarce. Two large multicenter cohort studies
with clinically diagnosed metabolic syndrome are the American
St. Jude Lifetime (SJLIFE, all types of childhood cancer) [6,7]
and the French Leucémies de l'Enfant et l'Adolescent (leukemia)
[31,51,52] studies. Other studies have yielded heterogeneous
and sometimes conflicting results and can be difficult to
compare. This may be due to metabolic syndrome components
being analyzed only separately, or due to small patient cohorts,
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a questionnaire based or retrospective design, insufficient
treatment data (eg, only childhood cancer diagnosis is known,
not treatment), and short follow-up (metabolic syndrome risk
increases continuously with age, so a follow-up of 10-20 years
likely underestimates this) [22,32,53-55]. In addition,
comparison of study outcomes can be difficult due to the use
of different classifications. Currently, no studies in national
cohorts on prevalence and determinants of metabolic syndrome
in childhood cancer survivors, including biomarkers and genetic
predisposition to metabolic syndrome, are available.
Here we describe the methodology of the Dutch LATER METS
study in the adult cohort of survivors treated between 1963 and
2002. This nationwide study assesses metabolic syndrome
prevalence, clinical and genetic risk factors, and the diagnostic
and predictive value of additional biomarkers. The results of
this study will be used to identify survivors at risk and to
optimize surveillance guidelines.
Table 1. NCEP-ATP IIIa and JISb classifications of metabolic syndrome, and alternative classification with adiposity measured by dual-energy x-ray
absorptiometry scan.
Alternative with dual-energy x-
ray absorptiometry scan
JISNCEP-ATP IIIMeasurementRequired for diagnosis
(≥3)
Body fat Z-score >2≥94c/80d,e>102c/88dWaist circumference (cm)Adiposity
≥5.5 or treatment≥5.5 or treatment≥5.5 or treatmentFasting glucose (mmol/L)Insulin resistance
≥1.7 or treatment≥1.7 or treatment≥1.7 or treatmentTriglycerides (mmol/L)Dyslipidemia






≥130/85 or treatment≥130/85 or treatment≥130/85 or treatmentBlood pressure (mmHg)Hypertension
aNCEP-ATP III = National Cholesterol Education Program Adult Treatment Panel III.
bJIS = Joint Interim Statement of International Diabetes Federation; National Heart, Lung, and Blood Institute; and the American Heart Association.
cMen.
dWomen.
eCut-off for Caucasian population.
Methods
Objectives
The objectives of this study are to assess 1) the prevalence and
risk factors (patient characteristics, previous treatment, and
genetic variation) of metabolic syndrome and its separate
components, compared to reference data, and 2) the potential
diagnostic and predictive value of novel biomarkers for
surveillance of metabolic syndrome in the national cohort of
adult long-term survivors of childhood cancer.
Study Population and Design
The Dutch LATER METS study is part of the nationwide Dutch
LATER study (Figure 1). This study started accrual in all 7
pediatric oncology centers in the Netherlands in 2016, thereby
inviting the national cohort of all survivors treated in these
hospitals between 1963 and 2002 to participate. Survivors were
identified from registries of children with newly diagnosed
cancer that are maintained in each of the 7 pediatric oncology
centers in the Netherlands. This study merged the available
information to create a specific childhood cancer survivors
registry containing all registered survivors. Dependent on
completeness of the sources in the centers, the starting year
varied from 1963 to 1977. The LATER METS study was
approved by the Medical Research Ethics Committee of the
Amsterdam University Medical Center (registered at
toetsingonline.nl, NL32117.018.10).
In the Dutch LATER study, data from 15 substudies of late
effects were collected, including cardiotoxicity, bone density,
frailty, growth hormone deficiency, renal toxicity, fatigue, and
psychological late effects. Individuals who survived at least 5
years after diagnosis of histologically confirmed malignancies
(as defined in the 3rd edition of the International Classification
of Childhood Cancer [56]) or Langerhans cell histiocytosis,
were treated with chemotherapy or radiotherapy, and were
between 0 and 17 years of age at diagnosis were invited.
Exclusion criteria were treatment for a malignancy in the past
year and living abroad.
For all eligible survivors, prior to the visit of the late-effects
clinic, sex; date of birth; date of cancer diagnosis; and detailed
data on cancer type and treatment, including chemotherapy
regimens and doses, radiotherapy fields and (fractionated) dose,
stem cell transplantation and corticosteroid treatments, were
collected in a pseudonymized, web-based, central database.
This includes primary diagnosis as well as, if present,
recurrences and subsequent malignancies.
Subsequently, data collection for all studies was combined with
the survivors’ regular care visit to the late-effects clinic for the
majority of survivors. Before the visit, survivors received
information about the study, sent by mail by the study personnel.
If they agreed to participate, study data was collected by the
treating physician or the study personnel.
The entire cohort, at formation in 2008, contained 6165 eligible
survivors. By mail, survivors were provided the option to opt-out
of future study participation. For the Dutch LATER study, the
cohort was frozen in 2016, leaving 5160 subjects eligible. For
the LATER METS study, only adults (n=4741) were invited.
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Inclusion took place until April 2020. Written informed consent was obtained from all study participants.
Figure 1. Overview of the Dutch LATER study cohort and embeddedness of the Dutch LATER METS study cohort within the underlying cohort.
Percentages indicate proportion of Dutch LATER cohort (N=6165).
Reference Population
Normative data from the Dutch Lifelines study cohort will serve
as reference population [57]. This is a 3-generation cohort of
167,000 inhabitants (10%) of the north of the Netherlands, from
whom, among other data, the following parameters relevant to
our study were collected between 2006 and 2013: age, sex,
height, weight, waist and hip circumference, blood pressure,
comorbidities, medication use, smoking, physical activity,
high-density lipoprotein, triglycerides, glucose,
apolipoprotein-B, low-density lipoprotein, total cholesterol, uric
acid, and high sensitivity C-reactive protein. We aim to use a
subset of this reference cohort as controls that have the same
age and sex distribution as our study cohort.
Data Collection
Data Collected Before Visit of Late-Effects Clinic
An overview of collected variables is presented in Table 2. In
addition to the previously mentioned data, the following
variables relevant for the Dutch LATER METS study were
extracted from the medical records: height and weight at cancer
diagnosis and relevant comorbidities.
Data Collected at Visit of Late-Effects Clinic
Weight was measured without shoes and with light clothing on
an electronic scale to the nearest 0.1kg. Height was measured
without shoes to the nearest centimeter. Body mass index was
calculated from weight and height. Waist circumference was
measured in the middle between the lower rib and iliac crest to
the nearest centimeter. Hip circumference was measured at the
greater trochanter to the nearest centimeter. Waist/hip ratio was
calculated. Blood pressure was measured after at least 5 minutes
rest with an electronic oscillometric meter (the mean of two
measurements).
Survivors completed a general health questionnaire, containing
questions about comorbidities, current medication use, smoking
and alcohol habits, education level, and family history of
diabetes mellitus and cardiovascular disease. They also
completed the Short Questionnaire to Assess Health enhancing
physical activity [58]. Total body dual-energy x-ray
absorptiometry scans (Hologic and Lunar types) were used to
assess body composition [41]. These measurements include fat
percentage and lean body mass. The 6-minutes walking test was
performed in a subset of the survivors (those treated in the
Sophia children’s hospital/Erasmus Medical Center, Rotterdam)
as a measure of functional exercise capacity [59,60].
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Table 2. Overview of collected variables.
Unit(s) or categoriesVariableCategoryCollection period




Name and armTreatment protocol
TCDbChemotherapy, per regimen
Radiotherapy field
TCD, fractions (if applicable)Cranial/craniospinal 
TCD, fractions (if applicable)Total body 
TCD, fractions (if applicable)Abdominal 
TCD, fractions (if applicable)Pancreas involvement 
Surgery procedure
Yes / No, conditioning regimenAutologous stem cell transplantation 
Yes / No, conditioning regimenAllogeneic stem cell transplantation 
Yes / NoRelapse
Male / FemaleSexPatient characteristics
DateDate of birth
DateDate of childhood cancer diagnosis
DateDate of study measurements (follow-up date)
CentimeterHeight at cancer diagnosisMedical history
KilogramWeight at cancer diagnosis
Yes / NoGrowth hormone deficiency
Yes / NoGrowth hormone replacement
Yes / NoHypothyroidism
Yes / NoHypogonadism
Yes / NoHypocortisolism with steroid replacement
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Unit(s) or categoriesVariableCategoryCollection period






Does the survivor have or has the survivor experiencedGeneral health questionnaire
Yes / No, age at diagnosisHigh cholesterol 
Yes / No, age at diagnosisHypertension 
Yes / No, age at diagnosisDiabetes mellitus 
Yes / No, age at diagnosisMyocardial infarction 
Yes / No, age at diagnosisStroke 
Type, dose, age at startMedication use
Yes / Former / NoSmoking status
Relative, type of disease, age at diag-
nosis
Cardiovascular disease in family
N/AN/AcQuestionnaire to Assess Health en-
hancing physical activity
PercentageTotal body fatDual-energy x-ray absorptiometry
scan
Z-scoreZ-score total body fat
Kilogram per m2Lean body mass
Kilogram per m2Appendicular lean body mass
MeterN/A6-minute walking test
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aICCC-3: International Classification of Childhood Cancer, edition 3.
bTCD: total cumulative dose.
cN/A: not applicable.
dIL-6: interleukin-6.
ehsTNF: high-sensitivity tumor necrosis factor alpha.
fIL-1: interleukin-1.
gIGF-1: insulin-like growth factor 1.
hLH: luteinizing hormone.
iFSH: follicle stimulating hormone.
jAMH: anti-Müllerian hormone.
Data Determined From Stored Samples
Venous blood samples were drawn after overnight fasting and
stored at -80°C in the biobank. To assess dyslipidemia, a lipid
spectrum will be measured, consisting of triglycerides,
high-density lipoprotein, low-density lipoprotein, total
cholesterol, and apolipoprotein-B. Insulin resistance will be
assessed by measuring glucose and insulin. Additionally,
adiponectin, leptin, and uric acid will be measured.
Inflammatory markers include high sensitivity C-reactive
protein, interleukin-6, high sensitivity tumor necrosis factor
alpha, and interleukin-1. The following possible confounders
will be measured: insulin-like growth factor 1, kidney function
(creatinine, urea), sex hormones (luteinizing hormone, follicle
stimulating hormone, anti-Müllerian hormone in women,
estradiol in women, testosterone in men), thyroid function
(thyroid-stimulating hormone, free thyroxine), cortisol.
DNA for analysis of single nucleotide polymorphisms will be
isolated from blood or, in survivors who received allogeneic
stem cell transplantation, saliva. Saliva was obtained by spitting
into a collection tube (Oragene kit) after not drinking or eating
for 30 minutes.
Metabolic Syndrome Definition
Metabolic syndrome will be classified according to definitions
by the third Adult Treatment Panel Report of the National
Cholesterol Education Program [37] and the Joint Interim
Statement of the International Diabetes Federation; National
Heart, Lung, and Blood Institute; and the American Heart
Association [38] (Table 1). Should these criteria be updated
during our analysis, we will strive to take these adjustments
into account.
Risk of Bias
Sex, date of birth, date of cancer diagnosis, and disease and
treatment data are also available for nonparticipating survivors.
Hence, comparing participating and nonparticipating survivors
in order to determine the risk of selection bias is feasible. We
will also compare these data between survivors with complete
and incomplete data to judge the risk of attrition bias. Neither
physician nor study personnel were blinded to the exposures of
the survivors. Objectively measurable outcomes will reduce the
risk of bias in this setting.
Statistical Analysis
Prevalence of Metabolic Syndrome
The percentage of subjects with metabolic syndrome and the
separate components will be assessed in survivors and in the
Lifelines reference cohort according to both aforementioned
metabolic syndrome definitions. Both cohorts will be compared
by Chi-square (or Fisher exact) test. The relative risk for
survivors to develop metabolic syndrome, compared to Lifelines
reference data, will be calculated by employing a log-binomial
regression model. The agreement between both metabolic
syndrome definitions will be investigated with kappa statistic,
in the whole cohort and stratified by sex.
A total body fat percentage of more than two standard deviations
above the mean, as assessed by dual-energy x-ray
absorptiometry, will be used as the most reliable marker for
adiposity. We will estimate the correlation between waist
circumference and fat percentage measured by dual-energy
x-ray absorptiometry scan, and we will compare overweight
classification with both definitions.
Risk Factors
Treatment-related risk factors for occurrence of metabolic
syndrome and the separate components will be assessed using
multiple uni- and multivariable logistic regression models. Based
on literature, an initial model will be built with cranial
radiotherapy, abdominal radiotherapy, and alkylating agents
(total alkylating dose calculated using cyclophosphamide
equivalent dose [61]) as treatment-related independent variables,
and age, sex, follow-up time, and smoking as patient-related
independent variables. The effect of potential additional risk
factors will be assessed by adding them to the initial model, and
variables with a P value <.20 will be kept in the final model.
These potential risk factors include all other chemotherapy
agents (type and total cumulative dose), other radiotherapy
fields (body location and dose), corticosteroids, education level,
family history, physical activity, functional exercise capacity,
and comorbidities.
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We will also investigate different abdominal radiotherapy fields
involved (pancreas, liver), and the influence of stem cell
transplantation conditioning regimens. We will also study
patient- and treatment-related risk factors for the outcome
underdiagnosis of overweight measured by waist circumference.
Biomarkers
Biomarker values will be reported, with reference values from
the local laboratory where the samples are measured. This will
be compared to Lifelines reference data by Chi-square (or Fisher
exact) test. A risk factor analysis of altered biomarker values
will be performed similarly to the abovementioned strategy for
risk factor analysis of metabolic syndrome occurrence.
The diagnostic and predictive value of the biomarkers to detect
metabolic syndrome will be investigated in multiple steps. We
will stratify the survivors by metabolic syndrome presence or
absence and compare mean or median values with the t test or
Mann-Whitney U test. We will evaluate sensitivity and
specificity and positive and negative predictive value based on
the reference values of the local laboratory where the samples
are measured. We will compare the area under the curve for a
model with metabolic syndrome components and for a model
with each biomarker added in order to investigate the additional
diagnostic value of the novel biomarkers. We will build
multivariable logistic regression models with metabolic
syndrome as dependent variable and the biomarker as
independent variable. In these models, we will also include
metabolic syndrome components as covariates in order to
investigate the independent predictive value of the novel
biomarkers. We will estimate the metabolic syndrome risk by
including the biomarker as categorical as well as continuous
variable.
Correlation (Pearson or Spearman) between biomarkers and fat
percentage by dual-energy x-ray absorptiometry scan will be
used to measure the potential use as surrogate markers for
adiposity.
Genetic Susceptibility Analysis
Genotyping will be performed with the Infinium Global
Screening Array [62] on DNA isolated from blood or, in
post-stem cell transplantation survivors, saliva. Quality control
of the genotype data will be performed following a standardized
protocol [63] including filtering based on call rate (excluded
when <0.975 for either single nucleotide polymorphism or
individual call rate), Hardy-Weinberg equilibrium, excess
heterozygosity, gender mismatches, and familial relationships.
Genetic ancestry will be assessed based on principal component
analysis. Imputation will be performed with the Michigan
Imputation Server using standard settings [64] with reference
panel Haplotype Reference Consortium version r1.1 [65].
The single nucleotide polymorphism analysis will be performed
with the RVtests software package [66] using multiple logistic
regression models with metabolic syndrome and its separate
components as outcomes. The initial analysis will be adjusted
for age at follow-up, sex, and genetic ancestry. Then, potentially
relevant covariates will be added to the model using forward
selection to study whether they influence the single nucleotide
polymorphism analysis; if so, they will be kept in the model.
These covariates include: body mass index at follow-up,
comorbidities (growth hormone deficiency, hypogonadism,
diabetes mellitus, and hypothyroidism), cranial and abdominal
radiotherapy, and alkylating agents (cyclophosphamide
equivalent dose). We will also perform a time-to-event analysis
(with left-censoring) on identified hits in order to get clinically
relevant effect estimates.
Quality control of the single nucleotide polymorphism analysis
will be performed with the EasyQC package using standard
settings [67]. This includes filtering based on minor allele
frequency (excluded when <0.05) and imputation quality
(excluded when <0.3).
Visualization of the genetic associations and annotation of
biological function for the top single nucleotide polymorphisms
will be performed with the FUMA platform [68]. Findings will
be replicated in available independent international cohorts.
Results
Patient Accrual
Patient accrual started in 2016 and lasted until April 2020. A
total of 2380/4741 survivors have participated (participation
rate 50.2%). From July 2020, biomarker testing, single
nucleotide polymorphism analysis, and data analysis will be
performed.
Power Calculation
We performed a power calculation with an expected prevalence
of metabolic syndrome in our study cohort of 30%. This
percentage is based on results from the SJLIFE cohort, in which
the prevalence of clinically diagnosed metabolic syndrome in
1598 survivors, after a mean of 25.6 years since diagnosis, was
31.8% [6]. This is the only large cohort study so far with
clinically diagnosed metabolic syndrome in survivors of
heterogeneous malignancies with a follow-up time comparable
to that of our cohort.
Based on the sample size of 2380 survivors, expected metabolic
syndrome prevalence of 30%, power of 80%, and type I error
of .05, we will have sufficient power to detect an approximate
3% difference in metabolic syndrome prevalence with the
reference cohort. For risk factor analysis among survivors, the
minimum detectable difference will depend on in how many
survivors the risk factor (eg, treatment regimen) is present. For
example, if the risk factor is present in 10%, 25%, or 50% of
survivors, a minimum difference of approximately 9%, 7%, or
6%, respectively, can be detected.
A genetic power calculator was used to estimate the relative
risk that can be found in the genetic susceptibility analysis for
an assumed minor allele frequency of 0.25 [69]. Based on the
sample size of 2380, metabolic syndrome population prevalence
of 15% [70], a power of 80%, a type I error of 5X10–8, and a
case-control ratio of 1:2, the relative risk per high risk allele
that can be found is 1.5.
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In the current study, we will assess the prevalence and patient-
and treatment-related risk factors for metabolic syndrome and
its separate components in adult survivors of childhood cancer,
as well as the additional diagnostic value of novel biomarkers
for surveillance, and the genetic susceptibility to
(treatment-related) metabolic syndrome by single nucleotide
polymorphism analysis.
A total of 2380 survivors have participated in the study. This
corresponds to 38.6% of all survivors (N=6165) in the Dutch
LATER cohort, and a participation rate of 50.2% of invited
adult survivors (n=4741). The definitive numbers of refusals,
nonresponders, deaths or otherwise excluded subjects are not
available yet. We will report these in the paper with the results
of our study.
Strengths of this study include the availability of a national
cohort of survivors, the availability of comprehensive disease
and treatment data, and the clinical assessment of late effects,
in addition to questionnaire based endpoints. So far, the role of
biomarkers and genetic susceptibility to metabolic syndrome
has not been well defined in survivors. We specifically intend
to use dual-energy x-ray absorptiometry scans and relevant
biomarkers (those with a high independent diagnostic or
prognostic value, and a high correlation with fat percentage on
dual-energy x-ray absorptiometry scan) to enable identification
of survivors at risk for metabolic syndrome, in whom waist
circumference measurement is not feasible due to abdominal
radiotherapy.
In conclusion, our study will provide knowledge on clinical and
genetic determinants of metabolic syndrome and the diagnostic
value of biomarkers in adult childhood cancer survivors. The
results of this study will be used to optimize surveillance
guidelines for metabolic syndrome among survivors, based on
enhanced risk stratification and screening strategies. This will
improve the diagnosis of metabolic syndrome and prevent
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